UBS Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-45,050
| Closed | -$10.4K | – | 10957 |
|
|
2024
Q4 | $10.4K | Buy |
45,050
+28,322
| +169% | +$34K | ﹤0.01% | 8301 |
|
|
2024
Q3 | $36K | Sell |
16,728
-4,825
| -22% | -$17.3K | ﹤0.01% | 7034 |
|
|
2024
Q2 | $111K | Buy |
21,553
+21,532
| +102,533% | +$113K | ﹤0.01% | 6100 |
|
|
2024
Q1 | $112 | Buy |
+21
| New | +$145 | ﹤0.01% | 8824 |
|
|
2023
Q4 | – | Sell |
-1,093
| Closed | -$4.32K | – | 10050 |
|
|
2023
Q3 | $4.32K | Buy |
+1,093
| New | +$4.09K | ﹤0.01% | 7450 |
|
|
2022
Q4 | – | Sell |
-50
| Closed | – | – | 11259 |
|
|
2022
Q3 | $0 | Sell |
50
-109
| -69% | -$886 | ﹤0.01% | 11081 |
|
|
2022
Q2 | $1K | Buy |
159
+109
| +218% | +$1.02K | ﹤0.01% | 10011 |
|
|
2022
Q1 | $1K | Sell |
50
-2,616
| -98% | -$46.8K | ﹤0.01% | 9957 |
|
|
2021
Q4 | $87K | Buy |
2,666
+2,186
| +455% | +$88.5K | ﹤0.01% | 6442 |
|
|
2021
Q3 | $21K | Sell |
480
-862
| -64% | -$42.1K | ﹤0.01% | 7123 |
|
|
2021
Q2 | $73K | Buy |
1,342
+1,006
| +299% | +$59.5K | ﹤0.01% | 6114 |
|
|
2021
Q1 | $25K | Sell |
336
-954
| -74% | -$99.1K | ﹤0.01% | 7184 |
|
|
2020
Q4 | $140K | Buy |
1,290
+670
| +108% | +$61.1K | ﹤0.01% | 5473 |
|
|
2020
Q3 | $55K | Sell |
620
-681
| -52% | -$77.4K | ﹤0.01% | 5587 |
|
|
2020
Q2 | $139K | Sell |
1,301
-373
| -22% | -$33.5K | ﹤0.01% | 5064 |
|
|
2020
Q1 | $99K | Sell |
1,674
-2,775
| -62% | -$188K | ﹤0.01% | 5305 |
|
|
2019
Q4 | $307K | Buy |
4,449
+2,185
| +97% | +$133K | ﹤0.01% | 5269 |
|
|
2019
Q3 | $235K | Buy |
2,264
+1,684
| +290% | +$159K | ﹤0.01% | 5122 |
|
|
2019
Q2 | $53K | Buy |
580
+79
| +16% | +$5.5K | ﹤0.01% | 5878 |
|
|
2019
Q1 | $46K | Buy |
501
+245
| +96% | +$17.1K | ﹤0.01% | 5617 |
|
|
2018
Q4 | $14K | Sell |
256
-948
| -79% | -$72K | ﹤0.01% | 7055 |
|
|
2018
Q3 | $144K | Buy |
1,204
+529
| +78% | +$61.4K | ﹤0.01% | 5288 |
|
|
2018
Q2 | $69K | Buy |
675
+411
| +156% | +$50.9K | ﹤0.01% | 5739 |
|
|
2018
Q1 | $34K | Sell |
264
-87
| -25% | -$9.51K | ﹤0.01% | 6001 |
|
|
2017
Q4 | $35K | Buy |
351
+241
| +219% | +$32.4K | ﹤0.01% | 6128 |
|
|
2017
Q3 | $16K | Buy |
110
+29
| +36% | +$5.45K | ﹤0.01% | 6614 |
|
|
2017
Q2 | $13K | Buy |
81
+3
| +4% | +$471 | ﹤0.01% | 6609 |
|
|
2017
Q1 | $12K | Sell |
78
-19
| -20% | -$2.32K | ﹤0.01% | 6516 |
|
|
2016
Q4 | $12K | Buy |
+97
| New | +$13.6K | ﹤0.01% | 6830 |
|
Other funds holding SYRS
BBA
1CM
XT
UBS Group's SYRS Position: Q1 2025 in Review
UBS Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 45,050 shares — an estimated $10.4K sold.
UBS Group first reported a position in SYRS in Q4 2016 and held it in 29 quarters. The position peaked at $307K in Q4 2019. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- UBS Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 45,050 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $10.4K.
- UBS Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 29 quarters.
- UBS Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $307K in Q4 2019.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.